Luye Pharma Group Ltd.
🇨🇳China
A Phase 1, MAD Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LY03017
Phase 1
Not yet recruiting
- Conditions
- Hallucinations and Delusions Associated With Alzheimer's Disease PsychosisHallucinations and Delusions Associated With Parkinson Disease PsychosisNegative Symptoms of Schizophrenia
- Interventions
- Drug: LY03017-Placebo
- First Posted Date
- 2025-05-20
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT06980207
- Locations
- 🇨🇳
Shanghai Mental Health Center, Shanghai, China
Effect of Food and Age on the Pharmacokinetics of LY03017
Phase 1
Not yet recruiting
- Conditions
- Alzheimer's Disease PsychosisParkinson Disease PsychosisNegative Symptoms of Schizophrenia
- Interventions
- First Posted Date
- 2025-01-27
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 26
- Registration Number
- NCT06793995
- Locations
- 🇨🇳
Shanghai Mental Health Center, Shanghai, China
Safety and Efficacy of LPM3770164 Sustained-release Tablets in Patients With Tardive Dyskinesia
Phase 1
Recruiting
- Conditions
- Tardive Dyskinesia (TD)
- Interventions
- Drug: LPM3770164 sustained release tablet 5 mgDrug: LPM3770164 sustained release tablet 10 mgDrug: LPM3770164 sustained release tablet 20 mgDrug: LPM3770164 sustained release tablet simulant
- First Posted Date
- 2024-12-12
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT06731868
- Locations
- 🇨🇳
Shanghai Mental Health Center, Shanghai, China
A Study Assessing the Safety and Tolerability of LY03020 in Chinese Healthy Subjects
Phase 1
Not yet recruiting
- Conditions
- SchizophreniaAlzheimer's Disease Psychosis
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-08-16
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 66
- Registration Number
- NCT06556966
Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC
Phase 3
Recruiting
- Conditions
- Relapsed Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-07-11
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 180
- Registration Number
- NCT06496048
- Locations
- 🇨🇳
Jilin Provincial Tumor Hospital, Jilin, China
Effect of Food on the Pharmacokinetics of LPM3770164 Sustained-release Tablets
Phase 1
Completed
- Conditions
- Huntington DiseaseTardive Dyskinesia
- Interventions
- Drug: LPM3770164 sustained release tablet
- First Posted Date
- 2024-06-25
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT06474650
- Locations
- 🇨🇳
Shanghai Mental Health Center, Shanghai, China
Phase II Clinical Trial to Evaluate the Efficacy and Safety of LPM3480392 Injection for Moderate to Severe Pain After Orthopedic Surgery
Phase 2
Recruiting
- Conditions
- Pain, Postoperative
- Interventions
- First Posted Date
- 2024-06-21
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 150
- Registration Number
- NCT06467409
- Locations
- 🇨🇳
Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
To Evaluate the Long-term Efficacy and Safety of Toludevenlafaxine Hydrochloride Sustained-release Tablets
Phase 4
Not yet recruiting
- Conditions
- Major Depressive Disorder
- Interventions
- First Posted Date
- 2024-05-23
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 736
- Registration Number
- NCT06426485
A Phase 1, SAD Study to Evaluate the Safety and Tolerability of LY03017
Phase 1
Not yet recruiting
- Conditions
- Hallucinations and Delusions Associated With Alzheimer's Disease PsychosisHallucinations and Delusions Associated With Parkinson Disease PsychosisNegative Symptoms of Schizophrenia
- Interventions
- Drug: LY03017-Placebo
- First Posted Date
- 2024-04-29
- Last Posted Date
- 2024-04-29
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT06388551
- Locations
- 🇨🇳
Shanghai Mental Health Center, Shanghai, China
First-in-Human Study of LPM6690176 in Patients With Advanced Solid Tumors.
- First Posted Date
- 2024-02-05
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 102
- Registration Number
- NCT06240546
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, China
© Copyright 2025. All Rights Reserved by MedPath